https://pacylex.reportablenews.com daily 1.0 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-and-heidelberg-pharma-present-zelenirstat-antibody-drug-conjugate-data-at-the-16th-annual-world-adc 2025-11-04T13:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-n-myristoyltransferase-inhibitors-highlighted-at-bio-annual-meeting 2025-06-10T13:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceutical-ceo-presents-n-myristoyltransferase-inhibitors-as-potential-payloads-for-adcs-at-2nd-annual-adc-payload-summit 2025-05-06T11:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/data-showing-pacylex-pharmaceuticals-lead-drug-zelenirstat-disrupts-oxidative-phosphorylation-in-breast-cancer-cells-will-be-presented-at-aacr-2025 2025-04-24T13:31:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-the-first-acute-myeloid-leukemia-aml-patient-dosed-with-zelenirstat-in-a-new-phase-1-2-clinical-trail 2025-03-17T13:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-presents-progress-on-nmt-inhibitors-for-cancer-at-february-industry-conferences 2025-02-03T18:21:58Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-appoints-michael-j-kamdar-to-board-of-directors 2024-11-07T18:23:45Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-ceo-presents-zelenirstat-for-cancers-at-the-bio-investors-forum 2024-10-14T13:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-publishes-a-new-myristoylation-inhibitor-mechanism-of-anti-cancer-activity-in-molecular-cancer-therapeutics 2024-10-10T13:57:32Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-recognized-as-bioalberta-s-company-of-the-year 2024-09-27T13:42:03Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-seeks-partners-for-new-adc-payload-class-n-myristoyltransferase-nmt-inhibitors 2024-09-03T12:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-publishes-phase-1-safety-and-efficacy-of-zelenirstat-in-cancer-patients-in-the-journal-investigational-new-drugs 2024-06-10T13:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-reports-zelenirstat-phase-1-safety-and-efficacy-data-at-asco-2024 2024-05-24T13:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-broad-spectrum-anti-cancer-drug-zelenirstat-at-2024-bio-international 2024-05-15T16:21:16Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-publishes-a-new-myristoylation-inhibitor-mechanism-of-anti-cancer-activity-in-the-journal-of-translational-medicine 2024-05-08T12:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-ceo-presents-zelenirstat-for-acute-myeloid-leukemia-at-the-world-orphan-drug-congress 2024-04-22T12:03:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-first-patient-dosed-in-a-phase-2a-study-of-zelenirstat-in-patients-with-refractory-metastatic-colorectal-cancer 2024-04-19T13:15:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-reports-zelenirstat-disrupts-oxidative-phosphorylation-in-cancer-cells-at-aacr-2024 2024-04-08T12:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-to-meet-with-investors-at-bio-ceo-conference-bcic-in-new-york-city-february-26-27-2024 2024-02-23T19:15:23Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-reports-phase-1-safety-and-efficacy-results-for-zelenirstat-in-colorectal-and-other-cancers 2024-01-17T17:48:38Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-major-milestones-in-2023-setting-stage-for-series-b-funding-and-clinical-expansion 2024-01-05T03:32:41Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-reports-safety-and-efficacy-results-from-its-phase-1-first-in-human-study-of-zelenirstat-pclx-001 2023-12-01T14:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-s-zelenirstat-shows-potent-in-vitro-radiosensitization-in-human-glioblastoma-models 2023-10-03T15:24:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-presents-new-data-on-the-mechanism-of-action-of-myristoylation-inhibition 2023-06-13T13:20:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-to-attend-2023-bio-international-convention 2023-05-31T15:51:20Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-first-patient-dosed-in-a-phase-2a-study-of-pclx-001-in-patients-with-relapsed-refractory-non-hodgkin-lymphoma 2023-05-18T09:37:12Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-reports-a-potential-drug-sensitivity-gene-signature-and-the-effects-of-myristoylation-inhibition-on-angiogenesis-and-cancer-cell-migration-at-american-association-of-cancer-research-aacr-2023 2023-04-13T12:01:48Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-selected-as-one-of-sixteen-canadian-startup-companies-to-present-at-sweet-biopharma-day-2023 2023-04-10T11:38:04Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-new-executive-team-members-as-the-company-accelerates-clinical-development-of-pclx-001 2023-01-17T11:38:14Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylexpharmaceuticals-targeting-cancer-with-novel-mechanism-and-precision-approach 2023-01-08T13:23:05Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-to-present-at-biotech-showcase-2023 2023-01-05T12:26:20Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-granted-fda-fast-track-designation-for-pclx-001-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia 2022-11-22T11:08:15Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-will-present-phase-1-clinical-experience-with-pclx-001-and-rationale-for-expanding-into-acute-myeloid-leukemia-patients-at-ash-2022 2022-11-03T10:42:03Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-announces-fda-clearance-of-ind-application-for-pclx-001-to-treat-acute-myeloid-leukemia 2022-11-02T16:28:59Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-announces-orphan-drug-designation-granted-to-pclx-001-for-the-treatment-of-acute-myeloid-leukemia 2022-10-14T10:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/major-grant-awarded-to-study-pclx-001-in-acute-myeloid-leukemia-patients 2022-10-11T10:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-presents-evidence-supporting-advancement-of-pclx-001-for-treatment-of-aml-at-aacr-2022 2022-04-08T10:39:48Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-publication-in-current-oncology-of-first-clinical-experience-with-an-n-myristoyltransferase-nmt-inhibitor-in-a-patient-with-diffuse-large-b-cell-lymphoma-dlbcl 2022-03-14T16:41:17Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-presented-initial-clinical-experience-with-pclx-001-in-patients-at-ash-2021 2021-12-13T10:24:18Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-the-initiation-of-a-phase-1-clinical-of-pclx-001-a-first-in-class-nmt-inhibitor-in-non-hodgkin-s-lymphomas-and-solid-tumor-patients 2021-09-14T15:56:41Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-presents-updates-on-the-journey-of-pclx-001-to-the-clinic 2021-06-15T13:00:30Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-closes-series-a-funding-to-advance-oncology-program-into-the-clinic 2021-06-02T09:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/health-canada-clears-pacylex-pharmaceuticals-for-new-phase-1-clinical-trial 2021-03-11T16:08:54Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-treatment-of-a-new-target-for-therapeutic-intervention-in-breast-cancer 2021-01-06T15:10:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-announces-publication-in-nature 2020-10-22T09:15:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-presents-as-medical-and-investment-conferences-go-virtual 2020-05-27T08:30:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-raises-us-3-9-million-to-advance-new-cancer-therapy-pclx-001-towards-clinical-trials 2020-03-04T08:00:10Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-discusses-new-oncology-target-and-drug-candidate-at-biotech-showcase-pclx-001-is-getting-ready-to-enter-clinical-trials 2020-01-09T08:00:00Z monthly 0.5 https://pacylex.reportablenews.com/pr/pacylex-targeting-cancer-with-novel-mechanism-and-precision-approach 2019-12-23T16:42:54Z monthly 0.5